Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sIPV booster co-administered with MMR and Hepatitis A vaccines in toddlers
NCT06442449Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Aug 2024
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis, measles, mumps and 2 more (5 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Seroconversion Rate of sIPV Neutralizing Antibody Against Poliovirus Type I at 30 days, Seroconversion Rate of sIPV Neutralizing Antibody Against Poliovirus Type II at 30 days and 5 more. Started Aug 2024; status: completed.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitismeaslesmumpsrubellahepatitis A (HAV)
Beyond the preview
Go deeper on NCT06442449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06442449.